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INTRODUCTION
Placental insufficiency (PI) is a syndrome caused 
by morphofunctional changes in the placenta, in 
which progression occurs along with fetal growth 
retardation syndrome (FGRS), often combined with 
hypoxia.[1-3] PI is one of the most common complications 
of pregnancy.[4-6] Perinatal mortality in women having 
suffered PI is 10.3% among full-term newborns and 
49% among pre-term infants.[4-6] FGRS due to PI is the 
second most common cause of perinatal mortality.[7-8]
According to the literature, risk factors for the 
development of PI and FGRS are divided into fetal 
and maternal.[9] The group of maternal factors includes 
somatic pathology, uterus pathology, family history of 
FGRS, and the presence of FGRS during a previous 
pregnancy, aggravated by obstetric-gynecological 
history.[9] Fetal-related causes include genetic diseases, 
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congenital deformities, multiple pregnancies, and 
congenital infections.[10,11]
MATERIALS AND METHODS
In total, 497 unrelated pregnant women in the third 
trimester of pregnancy were recruited for the study 
during the period 2009–2013. All participants signed 
an informed consent before entering the study. The 
clinical and laboratory examination of the participants 
was conducted in the perinatal center of the Saint 
Joasaph Belgorod Regional Clinical Hospital. The 
following inclusion criteria were used to check the 
eligibility of the participants: singleton pregnancy 
and Russian ethnicity. Patients having congenital 
malformations of internal genitals, uterine fibroids, 
anomalies and placental location, isosensitization of 
Rh factor or ABO, genetic diseases, and congenital 
malformations were excluded from the study.
A total of 250 participants were diagnosed with the 
syndrome of intrauterine growth retardation of varying 
severity. The diagnosis of the syndrome was based on 
clinical data, ultrasound fetometry (TOSHIBA Xario 
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SSA-660A) and parameters of growth and weight 
after the birth.
The assessment of the role of maternal and fetal risk 
factors in the formation of PI and FGRS was carried 
out using Chi-square test with the Yates correction for 
continuity. The calculations were performed in 2 × 2 
contingency tables.
The statistical data were processed using Statistica 6.0 
software package.[12]
RESULTS
Data on concomitant extragenital pathology, obstetric-
gynecological pathology, and familial thrombotic and 
obstetric-gynecological anamnesis are presented in 
Tables 1-3.
In both the groups, a high prevalence of somatic 
pathology was observed: Among pregnant women with 
FGRS, extragenital pathology was found in 60.00% 
of cases (n = 150) and in the control group - 51.42% 
(n = 127) (χ2 = 3.37, P = 0.07). As can be seen from 
the table, pregnant women with FGRS and the control 
group do not differ in the prevalence of individual 
somatic diseases.
It was established that the prevalence of spontaneous 
abortions is 1.84 times higher in the group of pregnant 
women with FGRS (18.40%) compared with the control 
Table 1: Characteristics of the extragenital pathology among pregnant women with FGR and without FGR
Extragenital pathology FGR patients, 
n=250 n (%)
Controls, 
n=247 n (%)
χ2, P
Hypertonic type and cardiac type of neurocirculatory dystonia 50 (20.00) 29 (11.74) 2.28, 0.13
Hypotonic type of neurocirculatory dystonia 34 (13.60) 28 (11.34) 0.39, 0.53
Chronic pyelonephritis, gestational pyelonephritis, chronic glomerulonephritis 63 (25.20) 55 (22.27) 0.44, 0.51 
Obesity 23 (9.20) 22 (8.91) 0.01, 1.00
Congenital heart defects 10 (4.00) 12 (4.86) 0.06, 0.81
Varicose veins 13 (5.20) 10 (4.05) 0.16, 0.69
Venous thromboembolism at pregnancy 4 (1.60) 1 (0.41) 0.78, 0.38
Chronic gastroduodenitis 26 (10.40) 22 (8.89) 0.17, 0.68
Thyroid hyperplasia 13 (5.20) 10 (4.01) 0.16, 0.69
Cerebrovascular disease in history 2 (0.80) 0 (0) 0.45, 0.50
FGR: Fetal growth retardation
Table 3: Characteristics of a thrombotic family history and a burdened obstetric‑gynecologic history of mothers 
among pregnant women with FGR and without FGR
Family history FGR patients, 
n=250 n (%)
Controls, 
n=247 n (%)
χ2, P
I. A depressed thrombotic anamnesis in parents, including: 54 (21.60) 25 (10.12) 11.40, 0.002
1.  Spontaneous venous thrombosis in parents, including varicose veins 
complicated by thrombosis (without phlebitis)
38 (15.20) 20 (8.10) 5.41, 0.02
2. Infants and infarcts in the parents who developed before the age of 50 13 (5.20) 5 (2.02) 2.74, 0.10
3. Combination of spontaneous venous thrombosis and stroke/infarction 3 (1.20) 0 (0) 1.32, 0.25
II.  The presence of an obstructed obstetrical anamnesis in the 
mother (habitual miscarriage, stillbirth, premature birth, severe 
preeclampsia)
21 (8.40) 8 (3.24) 5.12, 0.02
III. Combination of thrombotic and burdensome obstetric anamnesis 4 (1.60) 0 (0) 2.23, 0.14
FGR: Fetal growth retardation
Table 2: Characteristics of obstetric‑gynecological pathology among pregnant women with FGR and without FGR
Obstetric and gynecological pathology FGR patients, n=250 n (%) Controls, n=247 n (%) χ2, P
Medical abortion in history 80 (32.00) 65 (26.32) 1.68, 0.20
Infertility in history 5 (2.00) 8 (3.24) 0.34, 0.56
Miscarriage in history (total) 46 (18.40) 25 (10.12) 6.29, 0.01
Miscarriage in first trimester 36 (14.40 20 (8.10) 4.33, 0.04
Miscarriage in second trimester 10 (4.00) 5 (2.02) 1.05, 0.31
Ectopic pregnancy 10 (4.00) 15 (6.07 0.73, 0.39
Pregnancy loss in first trimester 12 (4.80) 12 (4.86) 0.01, 1.00
IVF pregnancy 2 (0.80) 2 (0.81) 0.01, 1.00
Disorders of the menstrual cycle in history 20 (8.00) 14 (5.67) 0.73, 0.39
Pelvic inflammatory disease in history 58 (23.20) 59 (23.89) 0.01, 0.94
Uterine scar 18 (7.20) 12 (4.86) 0.82, 0.36
Intrauterine infection during pregnancy 83 (33.20) 80 (32.39) 0.17, 0.68
Preeclampsia 55 (22.00) 68 (27.53) 1.75, 0.19
Antenatal intrauterine fetal death 4 (1.60) 0 (0) 2.23, 0.14
FGR: Fetal growth retardation, IVF: In-Vitro Fertilisation
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group (10.12%, χ2 = 6.29, P = 0.01), due to abortions 
in the first trimester (14.40% and 8.10%, respectively, 
χ2 = 4.33, P = 0.04) [Table 2]. In terms of the frequency 
of other obstetric and gynecological pathologies, the 
studied groups of pregnant women do not differ.
The studies of the thrombotic and aggravated obstetric 
history of parents of pregnant women with FGRS 
and without FGRS revealed significant differences 
[Table 3]. The parents of 54 patients with FGRS 
(21.60%) had a history of acute venous thrombosis 
or stroke/heart attack, which was significantly higher 
compared to 25 (10.12%) cases among pregnant 
women without FGRS (χ2 = 11.40, P = 0.002). 
Spontaneous venous thrombosis occurred in 15.2% 
of all cases among parents of patients with FGRS 
compared to 8.10% among parents of patients without 
FGRS (χ2 = 5.41, P = 0.02). 8.40% of mothers of 
patients with FGRS had a burdened obstetric history, 
which is higher than in control patients (3.24%, 
χ2 = 5.12, P = 0.02).
CONCLUSION
As a result of the study, it was established that 
pregnant women with FGRS have a higher incidence 
of spontaneous abortions in history. Furthermore, 
mothers of pregnant women with FGRS have a higher 
frequency of venous thrombosis or stroke/heart attack 
and more common obstetric history.
All these indicate that these maternal factors increase 
the risk of development of PI and FGRS.
Normal fetal growth depends on a genetically 
predetermined growth potential and is modulated by 
fetal, placental, maternal, and external factors. Fetuses 
with growth retardation syndrome are at high risk of 
neonatal and infant mortality.[13]
The results of our study are generally consistent with 
other data, which show that the risk group for FGRS is 
made up of pregnant women with burdened obstetric 
history (severe forms of preeclampsia, HELLP 
syndrome, eclampsia, premature placental abruption, 
habitual miscarriage, premature birth, antenatal fetal 
death, and unsuccessful IVF attempts); patients with 
recurrent thrombosis or an episode of thrombosis in a 
history or in this pregnancy, as well as a family history 
burdened by thrombosis.[14-16]
Arterial hypertension and preeclampsia associated 
with pregnancy cause disorders of the uterine artery 
perfusion, leading to uterine failure, a decrease in 
placental blood flow, placental dysfunction, affecting 
the oxygenation of the fetus, absorption of nutrients. 
PI can lead to poor circulation in the placenta and 
nutritional deficiencies, which affects the growth of 
the fetus and leads to fetal growth retardation.
Thus, as a result of the study, risk factors for the 
development of PI in FGRS are established. These 
include a burdened thrombotic history in relatives, a 
burdened obstetric history in the patient’s mother, and 
a history of spontaneous abortions.
The obtained results broaden the existing ideas 
about the role of maternal factors in the development 
of FGRS and make it possible to practice them in 
obstetrics.
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